



Contacts:

Baylor Research Institute  
Media: Ashley Howland 214-820-7540  
[www.baylorhealth.edu/Research/Default.htm](http://www.baylorhealth.edu/Research/Default.htm)

SBI Biotech Co. Ltd.  
Media: Atsuko Toda  
Phone number: +81-3-5789-3200  
[www.sbibiotech.jp](http://www.sbibiotech.jp)

**BAYLOR RESEARCH INSTITUTE ENTERS INTO A CONTRACT WITH SBI BIOTECH TO EXPAND FURTHER RESEARCH IN DC TECHNOLOGY**

DALLAS, TEXAS, USA, and TOKYO, JAPAN, October 2, 2008 – Baylor Research Institute (BRI), located in Dallas, Texas, and SBI Biotech Co., Ltd, a subsidiary of SBI Holdings, Inc., announced today that they will enter into a licensing and collaboration agreement to develop DC (dendritic cell) immunotherapy, one of the latest treatments for cancer.

Under the term of the agreement, BRI will grant to SBI Biotech a license in certain Asian countries under BRI's proprietary dendritic cell technology. BRI will also provide its technical expertise to aid SBI Biotech in the development of dendritic cell vaccines. SBI Biotech is to expand further research in DC technology through collaboration with Baylor Institute for Immunology Research (BIIR) at BRI. In addition, SBI Biotech will make efforts to promote DC immunotherapy in Japan through clinical experience at Kyoto University Hospital.

“We would like to seek for the possibilities such as building the consortium in cooperation with public research hospitals in Taiwan, Korea, and Japan,” said Ken-ichi Arai, M.D. Ph.D., president & CEO, SBI Biotech. “We also consider offering DC immunotherapy at private clinics. We will do our best to provide the most advanced DC immunotherapy available at BRI for cancer patients in Japan.”

“Baylor Research Institute is part of the Baylor Health Care System and is committed to bringing the latest in medical therapies from the laboratory bench to the patients”, said Dr. Michael A. E. Ramsay, M.D., FRCA, and President of BRI. “This collaboration with SBI Biotech will accelerate this process and broaden the research base so that we can help more patients worldwide. We are very excited by the opportunities this collaboration will bring to the future of medicine.”

Dr. Jacques Banchereau, Director of Baylor Institute for Immunology Research, said “We are very excited at the idea of working with our long term collaborator Dr. Arai and that it will permit us to accelerate the concept of cancer vaccine.”

**About DC (dendritic cell) immunotherapy**

DC immunotherapy is a kind of cancer therapy in which certain types of a patient's own immune cells(dendritic cells) are exposed to and assimilate tumor cell antigens. Dendritic cells carrying the tumor cell antigens then migrate to the patient's lymph nodes where they "teach" T lymphocytes to kill tumor cells. This therapy has some potential advantages such as fewer side effects, cancer cell-specific toxicity, and long-lasting beneficial effects on the immune system

**About Baylor Research Institute (BRI)**

Baylor Research Institute (BRI), with Michael Ramsay, MD, the President, is a dedicated research and treatment center for finding prevention therapies and treatments for diseases and illnesses. BRI develops cellular immunotherapies in collaboration with Baylor Institute for Immunology Research (BIIR) which most particularly concentrates on the study of dendritic cells. The programs at BIIR are led by Jacques Banchereau, Ph.D. For more information on BRI and BIIR, please refer to the websites at [www.baylorhealth.edu/Research/Default.htm](http://www.baylorhealth.edu/Research/Default.htm) and [www.baylorhealth.edu/Research/BIIR/BIIR.htm](http://www.baylorhealth.edu/Research/BIIR/BIIR.htm), each.

**About SBI Biotech Co., Ltd.**

SBI Biotech Co., Ltd, the drug subsidiary company of SBI Holdings, Inc. is conducting its business as the global bioventure company by assembling discovery pipelines from Japan, United States, China and Korea. SBI Biotech advances drug discovery and new therapy by utilizing the global network of SBI researchers, receiving investments from venture capital and by collaborating with pharmaceutical companies and university hospitals. For more information on SBI Biotech, please refer to the company's website at [www.sbibiotech.jp](http://www.sbibiotech.jp).

###